LifeMD Future Growth

Future criteria checks 2/6

LifeMD is forecast to grow earnings and revenue by 56.9% and 23.2% per annum respectively while EPS is expected to grow by 53.1% per annum.

Key information

56.9%

Earnings growth rate

53.1%

EPS growth rate

Healthcare Services earnings growth	28.7%
Revenue growth rate	23.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Apr 25

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

Mar 30

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Mar 13

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

Jan 05

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Dec 03

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Apr 17

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Nov 17

LifeMD launches at-home screening kits for breast, colon cancers

Sep 14

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

Aug 11

LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine

Jan 10

LifeMD: 4 Reasons You Should Avoid This Stock

Sep 29

LifeMD: Telehealth Growth Spectacular

Sep 17

LifeMD: 'Actual, Hard Numbers' Keep Us Bullish

Jul 13

Two class-action shareholder suits against LifeMD dropped

May 28

LifeMD (LFMD) Investor Presentation - Slideshow

May 01

Earnings and Revenue Growth Forecasts

NasdaqGM:LFMD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	245	-8	15	23	4
12/31/2024	201	-10	5	13	5
12/31/2023	153	-24	0	9	N/A
9/30/2023	136	-32	-7	1	N/A
6/30/2023	129	-33	-11	-3	N/A
3/31/2023	123	-39	-26	-17	N/A
12/31/2022	119	-49	-36	-23	N/A
9/30/2022	118	-55	-39	-27	N/A
6/30/2022	112	-61	-43	-31	N/A
3/31/2022	104	-64	-42	-32	N/A
12/31/2021	93	-62	-36	-33	N/A
9/30/2021	78	-75	-36	-34	N/A
6/30/2021	64	-85	-32	-31	N/A
3/31/2021	51	-73	-22	-22	N/A
12/31/2020	37	-63	-13	-12	N/A
9/30/2020	28	-32	-6	-5	N/A
6/30/2020	20	-9	-1	-1	N/A
3/31/2020	14	-5	0	0	N/A
12/31/2019	12	-3	0	0	N/A
9/30/2019	11	-3	0	0	N/A
6/30/2019	10	-3	0	0	N/A
3/31/2019	9	-3	-1	0	N/A
12/31/2018	8	-2	-1	-1	N/A
9/30/2018	6	-2	-1	-1	N/A
6/30/2018	6	-2	-1	-1	N/A
3/31/2018	5	-1	0	0	N/A
12/31/2017	4	-1	-1	-1	N/A
9/30/2017	5	-2	N/A	-1	N/A
6/30/2017	3	-1	N/A	-1	N/A
3/31/2017	4	-2	N/A	-1	N/A
12/31/2016	5	-1	N/A	0	N/A
9/30/2016	5	-1	N/A	0	N/A
6/30/2016	4	0	N/A	0	N/A
3/31/2016	3	0	N/A	0	N/A
12/31/2015	1	0	N/A	0	N/A
9/30/2015	1	0	N/A	0	N/A
6/30/2015	1	0	N/A	0	N/A
3/31/2015	1	0	N/A	0	N/A
12/31/2014	1	0	N/A	0	N/A
9/30/2014	1	0	N/A	0	N/A
6/30/2014	1	0	N/A	0	N/A
3/31/2014	1	0	N/A	0	N/A
12/31/2013	1	0	N/A	0	N/A
9/30/2013	1	0	N/A	0	N/A
6/30/2013	1	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LFMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LFMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LFMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LFMD's revenue (23.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: LFMD's revenue (23.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LFMD's Return on Equity is forecast to be high in 3 years time

LifeMD Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024

Price target increased by 20% to US$12.20

LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 12%

LifeMD, Inc. Provides Revenue Guidance for the Fourth Quarter and for the Full Year 2023

Price target increased by 9.7% to US$8.50

Recent updates

LifeMD, Inc., Annual General Meeting, Jun 14, 2024

LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors

LifeMD, Inc. to Report Q1, 2024 Results on May 08, 2024

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Price target increased by 20% to US$12.20

LifeMD, Inc. to Report Q4, 2023 Results on Mar 11, 2024

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

LifeMD: A GLP-1 Play With A Kicker

LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

LifeMD, Inc. announced that it expects to receive $10.000001 million in funding from Jason Pharmaceuticals, Inc.

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Insufficient new directors

Lifemd, Inc. Announces Resignation of Bertrand Velge from His Position as Member of the Board of Directors

Consensus EPS estimates fall by 12%

LifeMD, Inc. Provides Revenue Guidance for the Fourth Quarter and for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Price target increased by 9.7% to US$8.50

Independent Director recently bought US$501k worth of stock

Consensus EPS estimates fall by 57%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Share price stability

LifeMD, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 46% to US$7.67

LifeMD, Inc. Appoints William J. Febbo to Its Board of Directors

Independent Director recently bought US$170k worth of stock

Chairman & CEO recently bought US$105k worth of stock

Lifemd, Inc. Provides Earnings Guidance for the Second Quarter 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

LifeMD, Inc. to Report Q1, 2023 Results on May 12, 2023

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Consensus EPS estimates upgraded to US$0.46 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Appoints Dr. Joan Larovere to its Board of Directors

LifeMD, Inc. Appoints Jessica Friedeman as Chief Marketing Officer

No longer forecast to breakeven

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Price target decreased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LifeMD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

LifeMD, Inc. Appoints Bobby Jindal to the Board of Directors

LifeMD, Inc. Expands Primary Care Platform’s Diagnostic Capabilities with New At-Home Screening Kits For Early Warning Signs Of Cancer

LifeMD launches at-home screening kits for breast, colon cancers

Consensus EPS estimates fall by 15%

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Provides Consolidated Earnings Guidance for the Third Quarter 2022 and Full Year 2022

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

LifeMD, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus EPS estimates fall by 14%

Insider recently bought US$107k worth of stock

Lifemd, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. to Report Q1, 2022 Results on May 13, 2022

LifeMD, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$15.50

Forecast to breakeven in 2024

LifeMD, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS exceeds analyst expectations

LifeMD, Inc. to Report Fiscal Year 2021 Results on Mar 07, 2022

LifeMD, Inc. Launches Primary Care Platform Nationwide Following Beta Launch

LifeMD, Inc. Announces Appointment of Maria Stan as Controller and Principal Accounting Officer